Company news
Definium Therapeutics, Inc. (NASDAQ:DFTX) news
Definium Therapeutics, Inc. news releases on 6ix. Latest, Sep 14, 2026: Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study…
Press releases & updates
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
September 14, 2026
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
September 13, 2026
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
September 10, 2026
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
September 8, 2026
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
August 12, 2026
Definium Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 6, 2026
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2026
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
June 23, 2026
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 22, 2026
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
June 20, 2026
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 21, 2026
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
May 12, 2026
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 7, 2026
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
April 22, 2026
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
April 9, 2026
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
March 31, 2026
Definium Therapeutics Announces New Employee Inducement Grants
March 29, 2026
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
March 26, 2026
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
February 25, 2026
Definium Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2026
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
February 19, 2026
Definium Therapeutics Appoints Roger Adsett to Board of Directors
January 28, 2026
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
January 20, 2026
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026
January 13, 2026
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
January 12, 2026